Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities - Takeaways - MDSpire

Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities

  • By

  • Lifei Xu

  • Bin Wang

  • Wenwei Li

  • Xiandan Luo

  • Lixia Wang

  • Yi Zheng

  • May 13, 2026

  • 0 min

Share

  • 1

    Retinoblastoma primarily arises from biallelic inactivation of the RB1 gene, leading to dysregulation of the RB–E2F checkpoint.

  • 2

    Post-translational modifications (PTMs) like phosphorylation and ubiquitination significantly influence RB pathway functionality in retinoblastoma.

  • 3

    Less studied PTMs, including SUMOylation and lactylation, warrant further investigation for their roles in retinoblastoma.

  • 4

    Combination therapies targeting PTM enzymes with immunotherapy may enhance ocular preservation and manage metastasis in retinoblastoma.

  • 5

    Global survival rates for retinoblastoma vary significantly, with over 95% in high-income countries compared to around 50% in low-income regions.

Original Source(s)

Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities

  • by Lifei Xu, Bin Wang, Wenwei Li, Xiandan Luo, Lixia Wang, Yi Zheng

  • May 13, 2026

Related Content

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment